Explore AstraZeneca's recent Form 6-K detailing CEO Pascal Soriot's transfer of 136,537 shares as a gift. Discover the implications for shareholder dynamics and regulatory compliance.
Explore AstraZeneca's Q3 2025 financial performance highlighting an 11% revenue growth, improved margins, and a strong pipeline. A must-read for investors!
Explore AstraZeneca PLC's 6-K filing, detailing annual report compliance, important resolutions, and governance updates as of November 3, 2025.
Discover AstraZeneca PLC's latest 6-K report detailing voting rights, share capital, and compliance insights. Essential for investors and stakeholders in the biopharmaceutical sector.
AstraZeneca's 6-K filing details the approval of new articles of association, enhancing capital access. Key voting results and future trading updates included.
Discover AstraZeneca's latest Form 6-K report on Euan Ashley's director appointment at DexCom. Key insights on governance and compliance included.
AstraZeneca's Koselugo gains European approval for adults with NF1, showing 20% efficacy in trials. This marks a significant step in addressing rare disease treatment needs.
AstraZeneca's Tezspire is now approved in the EU for chronic rhinosinusitis with nasal polyps, addressing unmet medical needs. Significant trial results highlight its efficacy.
Discover AstraZeneca's latest financial report detailing Saphnelo's positive CHMP review for SLE treatment, trial insights, and future growth potential in autoimmune diseases.
Explore AstraZeneca's latest Form 6-K detailing Tezspire's FDA approval for CRSwNP, clinical trial successes, and market impact. Discover its potential in chronic respiratory care.
AstraZeneca's historic agreement with the U.S. government aims to lower drug prices by up to 80%. The deal includes a $50 billion investment in U.S. manufacturing and R&D, enhancing patient access.
Baxdrostat by AstraZeneca shows significant blood pressure reduction in Phase III trial, advancing treatment for resistant hypertension. Promising results showcase its safety and effectiveness.